• 20+ years as general surgeon, molecular biologist, & entrepreneur in cosmetic surgery.
• Pioneer in medical spa industry as owner/operator of multiple large chain practices generating $75M+ over 10 yrs.
• Commercialized multiple novel technologies including medical laser protocols, TBI treatments & biometric data acquisition (IoT).
• Piloted Root of Skin 3 years in practice; selected to commercialize PROVOQUE™.
• MD, UNC Chapel Hill; BS Biochemistry & Molecular Biology, NC State University.

• 30+ years, internationally recognized stem cell expert & entrepreneur in regenerative medicine; CEO Aivita Biomedical.
• Leads development of therapies for cancer, immune disorders, motor neuron disease, spinal cord injury, retinal disease, and a multi-pathogen vaccine kit.
• Leads Human Immunome Project, a global non-profit sequencing the immune system.
• Post Doctoral, Neurobiology, University of Cambridge; PhD Neurobiology & BS Cell Biology, The University of British Columbia.

• 25+ years leadership focused on life sciences & aesthetics in physician-dispensed, cash-pay companies, including Galderma/ALASTIN, Carl Zeiss, Metagenics, ResMed, Obalon, and Sequenom.
• Most recently Vice President Commercial Operations at ALASTIN Skincare (acquired by Galderma), scaling revenue by 4x in <4 years.
• Commercialized Obalon Therapeutics (cash pay, Class III medical device for weight loss) achieving $8M first year revenues.
• MBA, Santa Clara University; BS, U.S. Coast Guard Academy.

Dr. Julie Woodward is a nationally recognized leader in aesthetic and oculofacial surgery. She currently serves as Chief of Oculofacial Surgery at a major university, where she is also a Professor of Ophthalmology and an Associate Professor of Dermatology. With over 25 years of experience, Dr. Woodward has become one of the foremost authorities in aesthetic lasers and injectable treatments.

A prolific author and educator, Dr. Woodward has published more than 90 scientific journal articles and textbook chapters. She is a frequent invited speaker at premier national and international conferences and has served on the editorial boards of three aesthetic medicine journals. Her contributions to the field have earned her widespread recognition, including features in major fashion magazines and the distinction of being the first female oculofacial surgeon to appear on the cover of Plastic Surgery Practice Magazine.

Dr. Woodward was awarded the prestigious Henry Baylis Award in 2022 for her outstanding contributions to cosmetic surgery. She also serves on the Medical Board of the Aesthetic Institute Association.

As Chair of the LevEllis Scientific Advisory Board, Dr. Woodward brings deep clinical insight and scientific rigor to support the development of PROVOQUE and the future of regenerative aesthetics.

Dr. Jordan R. Plews is a biotechnology innovator and expert in stem cell biology, regenerative medicine, and biochemical engineering. He holds a PhD in Biochemical Engineering and Stem Cell Research from University College London, where his research contributed to major advances in cellular reprogramming and induced pluripotency. Following his doctoral studies, Dr. Plews completed postdoctoral training and business education at Stanford University, and previously held positions at Pfizer, Becton Dickinson, and Natera, before cofounding companies at the interface of science, medicine, and aesthetics.

Dr. Plews is the co-founder of Xytogen Biotech and ELEVAI Labs Inc., two pioneering companies in the cosmeceutical and regenerative skincare space. At ELEVAI, founded in 2020, he led the development of a portfolio of exosome-based skincare products that brought advanced stem cell science to medical aesthetics. Over the past decade, he has developed and launched more than 15 products in the aesthetic market, translating cutting-edge research in stem cells, regenerative medicine, and longevity science into commercially successful innovations.

Now serving on the Scientific Advisory Board of LevEllis Inc., Dr. Plews brings a unique combination of scientific depth and entrepreneurial insight to support the company’s mission of delivering validated, regenerative solutions for skin and hair through the PROVOQUE line.

Dr. Gabriel Nistor is a pioneering scientist in the field of regenerative medicine, with internationally recognized expertise in cell biology, translational medicine, regenerative medicine, ageing medicine, cancer immunology, vaccines against infectious diseases, and investigational product development.

After medical residency and several years of practicing general medicine, between 2000 to 2010, Dr. Nistor conducted foundational research at the University of California Irvine in the department of Neurobiology and Medicine as a post-doctoral researcher. He co-developed the first human embryonic stem cell-derived treatment for acute spinal cord injury in animal models, which was subsequently approved by the FDA for human clinical trials—the first of its kind in the U.S.

Joining the medical industry currently as a Chief Science Officer, Chief Medical Officer and Scientific and Clinical Consultant, Dr. Nistor applies his medical knowledge and experience to develop safe and efficacious biologic drugs and cell therapies for multiple indications.

At AIVITA Biomedical, Dr. Nistor plays a critical role in the advancement of autologous dendritic cell vaccines against solid tumors and pathogens and continues to contribute groundbreaking innovations in cellular manufacturing, product development, and translational science, refining processes for tumor stem cell isolation and dendritic cell activation, and discovering novel potency assays and biomarkers to guide personalized treatment.

His recent work includes isolating and expanding circulating tumor cells, identifying immune-escape mechanisms, and advancing tumor stem cell-derived antigen strategies for personalized vaccines across multiple cancer types. The autologous dendritic cell vaccine developed initially against CoViD during the pandemic and recently against multiple pathogens, was tested in a phase I and II clinical trials and proveen to be superior to all available vaccines, including from the safety aspect to the extent of protection as duration and diversity of variants.

As a CMO, Dr. Nistor conducts clinical trials for regenerative medicine targeting osteoarthritis, sarcopenia, obesity, hepatic steatosis, immune aging and longevity. He designs and writes clinical protocols, maintains the FDA communications, the relations with CROs and investigators following the principles of good clinical practices.  As a Scientific Advisor he oversees the manufacturing and clinical development of an autologous cell-based product for the treatment of Alzheimer’s diseases, currently in clinical trials.

In addition to medical industry activities, Dr. Nistor contributes as faculty in continuous medical education programs at American Academy of Anti-Aging Medicine (A4M) with lectures on developmental and translational medicine, and at University California Irvine on good clinical practices for clinical investigators.

Dr. Nistor has been awarded over $20 million in competitive research grants from CIRM, NIH, and other funding bodies. As a member of the LevEllis Scientific Advisory Board, he brings unparalleled scientific depth and translational insight to support the development of next-generation regenerative products including the PROVOQUE line.